GB202015056D0 - Biomarkers - Google Patents
BiomarkersInfo
- Publication number
- GB202015056D0 GB202015056D0 GBGB2015056.1A GB202015056A GB202015056D0 GB 202015056 D0 GB202015056 D0 GB 202015056D0 GB 202015056 A GB202015056 A GB 202015056A GB 202015056 D0 GB202015056 D0 GB 202015056D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- biomarkers
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Priority Applications (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2015056.1A GB202015056D0 (en) | 2020-09-23 | 2020-09-23 | Biomarkers |
| US18/027,874 US20230348983A1 (en) | 2020-09-23 | 2021-09-23 | Biomarkers |
| CN202180078581.9A CN116867910A (zh) | 2020-09-23 | 2021-09-23 | 生物标志物 |
| JP2023518817A JP2023543763A (ja) | 2020-09-23 | 2021-09-23 | バイオマーカー |
| PCT/GB2021/052469 WO2022064198A1 (en) | 2020-09-23 | 2021-09-23 | Biomarkers |
| EP21782794.8A EP4217507A1 (en) | 2020-09-23 | 2021-09-23 | Biomarkers |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2015056.1A GB202015056D0 (en) | 2020-09-23 | 2020-09-23 | Biomarkers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB202015056D0 true GB202015056D0 (en) | 2020-11-04 |
Family
ID=73139042
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GBGB2015056.1A Ceased GB202015056D0 (en) | 2020-09-23 | 2020-09-23 | Biomarkers |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230348983A1 (https=) |
| EP (1) | EP4217507A1 (https=) |
| JP (1) | JP2023543763A (https=) |
| CN (1) | CN116867910A (https=) |
| GB (1) | GB202015056D0 (https=) |
| WO (1) | WO2022064198A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250028934A1 (en) * | 2023-07-17 | 2025-01-23 | The Toronto-Dominion Bank | Systems and methods for time series prediction using multi-stage computation |
| US20250263702A1 (en) * | 2024-02-19 | 2025-08-21 | Flagship Pioneering Innovations Vii, Llc | Rnai agents targeting cideb and related methods |
| WO2025230979A1 (en) * | 2024-04-30 | 2025-11-06 | Flagship Pioneering Innovations Vii, Llc | Tnfaip3-targeted compositions and related methods |
| WO2026038054A2 (en) * | 2024-08-15 | 2026-02-19 | Genome Research Limited | Novel companion diagnostic method |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1650192A1 (en) | 2003-07-24 | 2006-04-26 | Astellas Pharma Inc. | Quinolone derivative or salt thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2310504A1 (en) * | 2008-07-03 | 2011-04-20 | Santaris Pharma A/S | Rna antagonist compounds for the inhibition of expression of mitochondrial glycerol-3-phosphate acyltransferase 1 (mtgpat1) |
| EP2475781B1 (en) * | 2009-09-11 | 2017-10-25 | The Chinese University Of Hong Kong | Methods for assessing liver pathologies |
| JP2018169277A (ja) * | 2017-03-29 | 2018-11-01 | 国立大学法人神戸大学 | 炎症性関連病態を伴う非アルコール性脂肪性肝疾患のバイオマーカー |
| US11808772B2 (en) * | 2017-07-19 | 2023-11-07 | Bio-Rad Europe Gmbh | Biomarker combinations to simultaneously evaluate non-alcoholic steatohepatitis and hepatic fibrosis status |
| IT201800006129A1 (it) * | 2018-06-08 | 2019-12-08 | Uso dello SNP rs17618244 come marcatore predittivo nella NAFLD. | |
| WO2020044497A1 (ja) * | 2018-08-30 | 2020-03-05 | 国立大学法人 東京大学 | Ｎａｆｌｄ又はｎａｓｈの検出又はリスクの予測方法、ｎａｆｌｄ又はｎａｓｈを検出するための診断薬キット、対象における肝線維化の進行度の判定方法、及び対象における肝線維化の進行度を判定するための診断薬キット |
-
2020
- 2020-09-23 GB GBGB2015056.1A patent/GB202015056D0/en not_active Ceased
-
2021
- 2021-09-23 JP JP2023518817A patent/JP2023543763A/ja active Pending
- 2021-09-23 EP EP21782794.8A patent/EP4217507A1/en active Pending
- 2021-09-23 CN CN202180078581.9A patent/CN116867910A/zh active Pending
- 2021-09-23 US US18/027,874 patent/US20230348983A1/en active Pending
- 2021-09-23 WO PCT/GB2021/052469 patent/WO2022064198A1/en not_active Ceased
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1650192A1 (en) | 2003-07-24 | 2006-04-26 | Astellas Pharma Inc. | Quinolone derivative or salt thereof |
Non-Patent Citations (13)
| Title |
|---|
| ALIENS, J HEPATOL, vol. 71, no. 6, 2019, pages 1229 - 1236 |
| BRUNNER ET AL., NATURE, vol. 574, no. 7779, 2019, pages 538 - 542 |
| CHAUDHARY ET AL., CLIN. CANCER RES., vol. 25, 2019, pages 463 - 472 |
| DYSON ET AL., FRONTLINE GASTROENTEROLOGY, vol. 5, 2014, pages 211 - 218 |
| FARMERY ET AL., SCI. REP., vol. 8, 2019, pages 1 - 17 |
| HADFIELD, J. STAT. SOFTW., vol. 33, 2010, pages 1 - 22 |
| KLEINER ET AL., HEPATOLOGY, vol. 41, no. 6, 2005, pages 1313 - 1321 |
| LIDURBIN, BIOINFORMATICS, vol. 26, 2010, pages 589 - 595 |
| MARTINOCORENA ET AL., CELL, vol. 171, 2017, pages 1029 - 1041 |
| MOLECULAR PHARMACOLOGY, vol. 78, no. 5, 2010, pages 961 - 970 |
| RHEINBAY ET AL., NATURE, vol. 578, 2020, pages 102 - 111 |
| SOOKOIAN ET AL., J LIPID RES, vol. 50, 2009, pages 2111 - 6 |
| WIEMANN ET AL., FASEB J, vol. 16, 2002, pages 935 - 42 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023543763A (ja) | 2023-10-18 |
| EP4217507A1 (en) | 2023-08-02 |
| WO2022064198A1 (en) | 2022-03-31 |
| US20230348983A1 (en) | 2023-11-02 |
| CN116867910A (zh) | 2023-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB201919219D0 (en) | Cancer biomarkers | |
| GB202015056D0 (en) | Biomarkers | |
| GB201911947D0 (en) | Miscarriage biomarkers | |
| GB201908780D0 (en) | Melanoma biomarkers | |
| GB202103080D0 (en) | Cancer biomarkers | |
| GB201902077D0 (en) | Biomarkers | |
| GB202014190D0 (en) | Biomarkers | |
| GB201900677D0 (en) | Biomarkers | |
| GB202112831D0 (en) | Biomarker | |
| GB202103951D0 (en) | Biomarkers | |
| GB202107813D0 (en) | Biomarker | |
| GB201914183D0 (en) | Biomarker | |
| GB201913846D0 (en) | Biomarker | |
| GB201912154D0 (en) | Biomarker | |
| GB201911078D0 (en) | Biomarker | |
| GB202114655D0 (en) | Biomarkers | |
| GB202111201D0 (en) | Biomarkers | |
| GB202103140D0 (en) | Biomarkers | |
| GB202005435D0 (en) | Biomarkers | |
| GB202001361D0 (en) | Biomarkers | |
| GB201914096D0 (en) | Cancer Biomarker | |
| GB202114656D0 (en) | Biomarker | |
| GB202110365D0 (en) | Biomarker | |
| GB202314954D0 (en) | Biomarkers | |
| GB202216295D0 (en) | Biomarkers |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AT | Applications terminated before publication under section 16(1) |